ABCSG 45 Summary

A prospective, open, randomized, phase II study of carboplatin/ olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status

Start:	06/2019
Coordinating Investigator:	Christian Singer, Vienna
Sample size:	90 (national)
Design: (Click to enlarge)